NEUWAY Pharma
NEUWAY Pharma is developing an entirely novel class of biotherapeutics built around its proprietary Engineered Protein Capsules (EnPC®), which can cross the blood-brain barrier and deliver transformative neuropharmaceuticals for the treatment of disorders of the central nervous system (CNS).
The company aims to be the partner of choice for antibody and mRNA drug developers who need to overcome the current hurdles of delivering these and other drug modalities into the brain and CNS tissue.
Operating as a drug developer and a delivery expert, NEUWAY will demonstrate and exploit the value of its technology through its internal rare disease pipeline for indications with a high unmet medical need as well as partnered programs.
Meet us
Mar 30-31, 2023, 10th Annual Peptides & Oligonucleotides Congress, London, UK
Mar 28-Apr 1, 2023, Brain Barriers, CSHL
May 3-4, 2023, LSX World Congress, London, UK
June 06-07, 2023, Neuroscience Drug Development Europe, Berlin, Germany
News
NEUWAY/Fraunhofer SCAI predicting interaction of EnPC® proteins with brain receptors applying AI
2022-02 EPR Article Drug Delivery feat. NEUWAY (Vol 27, Issue 1)
2021-06 nature journal: Crossing the barrier to treating brain diseases
Jobs